Serum Institute of India, which is currently producing the widely used vaccine in India – Covishield began the production of the first batch of Covovax COVID-19 vaccine, developed by US’ Novavax.
The Indians rested many hopes on this new vaccine as there is an immediate need to scape up the production of vaccines as the country is planning high vaccination drives in the future. The new COVID delta plus variant is a concern as the experts rated its transmission rate as ‘very high’.
Under these circumstances, SII CEO, Adar Poonawalla said, “The vaccine has great potential to protect our future generations below the age of 18.” It is known that the Delta variant hits the children predominantly and it is widely proven in the other countries of the world.
So, with Adar Poonawalla expressing his confidence over the Covovax and its efficacy in children, this has become a product of demand in India even before its availability.
The US biotechnology company Novavax’s protein-based vaccine, NVX-CoV2373, has demonstrated 100% protection against moderate and severe disease, and 90.4% overall efficacy, in its Phase 3 trial.
It is known that along with Bharat Biotech’s Covaxin, SII’s Covishield, and Covovaxin, Russia’s Sputnik V has also cleared by the Indian government for medical use.